


Stereoselective and Regiodivergent Allylic Suzuki–Miyaura Cross-Coupling of 2-Ethoxydihydropyranyl Boronates: Synthesis and Confirmation of Absolute Stereochemistry of Diospongin B

Taras Rybak and Dennis G. Hall*

Department of Chemistry, Centennial Centre for Interdisciplinary Science, University of Alberta, Edmonton, Alberta T6G 2G2, Canada

S Supporting Information

ABSTRACT: Oxygen-containing heterocycles such as pyrans are a common substructure present in a variety of natural products and pharmaceutical drugs. Highly functionalized 4- and 6-aryl/heteroaryl dihydropyran derivatives are assembled by a highly stereoselective, ligand-controlled regiodivergent sp^3 – sp^2 Suzuki–Miyaura cross-coupling of a 2-ethoxy dihydropyranyl boronate derived from a catalytic enantioselective inverse-electron-demand oxa[4 + 2] cycloaddition. The scope and selectivity of this method were assessed along with an application to a concise total synthesis of the diarylheptanoid natural product diospongin B.



A large number of naturally occurring compounds contain polysubstituted pyran units (Figure 1). These substances





Figure 1. Natural products and pharmaceutical drugs containing a polysubstituted pyran unit.

tend to display a wide range of biological properties, including antibiotic and anticancer activity.¹ The presence of carbon-containing fragments at positions 2-, 4-, and 6-, often in various combinations, is quite frequent. Members of these classes include goniothalesdiol A,² as well as several macrolides such as (–)-zampanolide.^{3,4} Pyran-containing molecules also have potential value in medicinal chemistry, as shown in the recent synthesis of a potent dipeptidyl peptidase-4 (DPP-4) inhibitor omarigliptin (MK-3102) developed in the Merck research laboratories.⁵ The ubiquity of this “privileged” substructure both in nature and pharmacopeia warrants further development of alternate methods of synthesis.

Although various methods to introduce heteroatoms on a dihydropyran framework exist, few methods can selectively install carbon-based fragments especially through catalytic C–C coupling. Advances in catalyst-controlled regioselective Suzuki–Miyaura cross coupling of simple allylic boronates were recently reported by Organ⁶ and Yang and Buchwald,⁷ as well as stereoretentive coupling of optically enriched allylboronates by Aggarwal and Cruden.⁸ These studies inspired us to investigate the feasibility of stereoselective and regiodivergent cross-couplings of more complex heterocyclic allylboronates. In this regard, we recently reported that chiral enantiomerically

enriched heterocyclic allylic boronates **1** and **2** can be coupled with high stereochemical retention with a wide variety of aryl and alkenyl halides to afford, independently, both regioisomeric 2- and 4-substituted dehydropiperidines **3** and **4** and dihydropyrans **5** and **6** in >95:5 enantiomeric ratio (Scheme 1).⁹ These highly valuable compounds are obtained in high selectivity by way of a catalyst-controlled regiodivergent mechanism. Because 2,6-disubstituted pyrans constitute a common motif in nature, we were motivated to expand the scope of this cross-coupling method to include dihydropyranyl boronate substrates of higher complexity. In particular, the use of 2-alkoxyated substrates would provide a convenient

Scheme 1. Suzuki–Miyaura Cross-Coupling of Heterocyclic Allylic Boronates




Received: July 3, 2015

Published: August 20, 2015

functional group to further transform the resulting cross-coupling products. To this end, we planned to evaluate the suitability of 2-ethoxy dihydropyranyl boronate **7** produced by the enantioselective oxa[4 + 2] cycloaddition¹⁰ catalyzed by Jacobsen's chiral chromium complex **10** (Scheme 1).¹¹

Initially, it was uncertain whether our previously optimized cross-coupling conditions for allylboronate **2** would be suitable for substrate **7**.⁹ Nonetheless, previous reaction conditions were used as a starting point toward the identification of an optimized regioselective synthesis of α - and γ -products **11a** and **12a** (Table 1).¹² The standard conditions previously used with **2** for the

Table 1. Optimization of the α Regioisomer **11a**^a




entry	Pd source	ligands	base	temp (°C)	yield (%) ^c	α : γ ^d
1	(Allyl)PdCl ₂	(p-CF ₃ C ₆ H ₄) ₃ P	K ₃ PO ₄	70	64	84:16
2	(Allyl)PdCl ₂	(p-CF ₃ C ₆ H ₄) ₃ P	KOH	70	26	83:17
3	(Allyl)PdCl ₂	(p-F ₃ C ₆ H ₄) ₃ P	K ₃ PO ₄	70	54	85:15
4	(Allyl)PdCl ₂	PPh ₃	K ₃ PO ₄	70	43	83:17
5	Pd-PEPPSI-IPr	—	K ₃ PO ₄	70	49	50:50
6	Pd-PEPPSI-IPent	—	K ₃ PO ₄	70	16	74:26
7 ^b	(Allyl)PdCl ₂	Xantphos	K ₃ PO ₄	70	16	55:45
8 ^b	(Allyl)PdCl ₂	dppf	K ₃ PO ₄	70	50	55:45
9 ^b	(Allyl)PdCl ₂	Ph ₂ P(CH ₂) ₃	K ₃ PO ₄	70	32	57:43
10 ^b	(Allyl)PdCl ₂	Ph ₂ P(CH ₂) ₄	K ₃ PO ₄	70	21	76:24
11	(Allyl)PdCl ₂	(p-CF ₃ C ₆ H ₄) ₃ P	K ₃ PO ₄	85	73	83:17

^aReaction scale: *rac*-**7** (0.30 mmol, 1.2 equiv), 4-bromoanisole (0.25 mmol, 1.0 equiv), Pd catalyst (3.75 mmol, 1.5 mol %), ligand (15 mmol, 6 mol %), base (1.25 mmol, 4 equiv) unless indicated otherwise. ^b3.1 mol % of ligand used. ^cIsolated yield of the major regioisomer **11a**. ^dRegioisomer ratio (α : γ) was measured from the ¹H NMR spectra of crude products. Ligands: Xantphos = 4,5-bis-(diphenylphosphino)-9,9-dimethylxanthene; dppf = 1,1'-bis-(diphenylphosphino)ferrocene.

synthesis of α -isomers, [(allyl)PdCl]₂ with potassium phosphate as a base in acetonitrile, proved to be efficient toward the synthesis of **11a**.⁹ Under these conditions, **11a** was obtained selectively (84:16) in moderate yield (entry 1). These conditions could not be improved using an alternate base (KOH) that was optimal toward the piperidine allylboronate **1** (entry 2).⁹ Previous work on **2** showed that α -selectivity was favored with the use of weaker σ -donating ligands. With **7**, however, the yield and selectivity could not be improved when tris(4-fluorophenyl)phosphine was used (entry 3). Organ's Pd-PEPPSI-*i*-Pr and Pd-PEPPSI-*i*-Pent catalysts (entries 5 and 6), previously known to offer high α -selectivity,^{6,9} as well as bidentate phosphine ligands (entries 7–10), showed no improvement of regioselectivity or yield. Upon increasing the reaction temperature to 85 °C using the same conditions as entry 1, the regioselectivity for **11a** improved to a ratio of 83:17 with an acceptable yield of 73% (entry 11).

The previous reaction conditions used toward the efficient synthesis of the γ -isomer **6** were applied to the synthesis of **12a** (Table 2).⁹ Strong σ -donating alkylphosphine ligands such as XPhos favored the formation of the γ -product **12a** with very high regioselectivity (entry 1). Although every dialkylarylphosphine ligand that was tested gave similarly high regioselectivity,

Table 2. Optimization of the γ Regioisomer **12a**^a




entry	Pd source	ligands	base	temp (°C)	yield (%) ^b	α : γ ^c
1	(Allyl)PdCl ₂	XPhos	K ₃ PO ₄	40	82	7:93
2	(Allyl)PdCl ₂	CyJohnPhos	K ₃ PO ₄	40	61	6:94
3	(Allyl)PdCl ₂	RuPhos	K ₃ PO ₄	40	75	5:95
4	(Allyl)PdCl ₂	SPhos	K ₃ PO ₄	40	86	5:95

^aReaction scale: *rac*-**7** (0.30 mmol, 1.2 equiv), 4-bromoanisole (0.25 mmol, 1.0 equiv), Pd catalyst (3.75 mmol, 1.5 mol %), ligand (15 mmol, 6 mol %), base (1.25 mmol, 4 equiv). ^bIsolated yield of the major regioisomer **12a**. ^cRegioisomer ratio (α : γ) was measured from the ¹H NMR spectra of crude products. Ligands: XPhos = 2-(dicyclohexylphosphino)-2',4',6'-triisopropylbiphenyl; CyJohnPhos = 2-(dicyclohexylphosphino)biphenyl; RuPhos = 2-(dicyclohexylphosphino)-2',6'-diisopropoxybiphenyl; SPhos = 2-(dicyclohexylphosphino)-2',6'-dimethoxybiphenyl.

SPhos was the optimal one, affording **12a** in 86% yield and 95:5 regioselectivity (entry 4). With the optimized conditions for regiodivergent synthesis of both α - and γ -regioisomers in hand, the scope of aryl bromides was explored next.

As described previously by our group and others, the synthesis of substrate **7** involves the enantioselective hetero[4 + 2] cycloaddition between ethyl vinyl ether **8** and boronoacrolein **9** catalyzed by Jacobsen's tridentate chromium complex **10**.¹⁰ This transformation was applied in a number of three-component stereoselective oxa[4 + 2] cycloaddition/allylboration reactions toward the synthesis of numerous bioactive molecules.^{10a,13} To begin the evaluation of the reaction scope, we prepared cycloadduct **7** in a good yield with high enantioselectivity (77%, 95% ee) using carefully distilled **9**, 4 Å molecular sieves as the drying agent, and a 3 mol % loading of **10** (Scheme 2).¹⁴

A range of sp²-hybridized organobromide substrates were tested to demonstrate the general efficiency of this method. The α -coupling products **11a–e** were isolated in good yields with high regioselectivity. The regioselectivity was lower for the coupling product **11a** of electron-rich *p*-methoxyphenyl bromide (83:17 α : γ) relative to the product **11b** of the electron-poor *p*-(trifluoromethyl)phenyl bromide (93:7 α : γ). The *N*-Boc-5-bromoindole substrate, which was not investigated in our previous work,⁹ afforded **11d** in high regioselectivity (90:10 α : γ). Alkenyl bromides appear to be suitable with this method. The reaction between **7** and β -bromostyrene afforded **11e** in high yield and high regioselectivity (81%, 91:9 α : γ). The conditions used toward the synthesis of γ -products resulted in a slightly improved yield over the α -isomers. Thus, product **12a** of *p*-methoxyphenyl bromide was obtained in a slightly higher yield (86%) and regioselectivity (5:95 γ : α) over the product **12b** of the electron-deficient (trifluoromethyl)phenyl bromide (80%, 8:92 α : γ). The conditions favoring γ -selectivity with the *N*-Boc-5-bromoindole gave **12d** in a very high yield (97%) and high regioselectivity (3:97 α : γ). Surprisingly, the reaction between **7** and β -bromostyrene gave **12e** in a yield (80%) and regioselectivity (2:98 α : γ) higher than our previous example between **2** and β -bromostyrene (70%, 25:75 α : γ).⁹ With all examples, there did not appear to be any indication of the


Scheme 2. Scope of sp^2 -Hybridized Organobromides^{a,b}

^aReaction scale: 7 (0.30 mmol, 1.2 equiv), RBr (0.25 mmol, 1.0 equiv), Pd catalyst (3.75 mmol, 1.5 mol %), ligand (15 mmol, 6 mol %), base (1.25 mmol, 4 equiv). ^bRegioisomer ratio (α:γ) was measured from the ¹H NMR spectra of crude products. ^cDiastereomeric ratio was determined by chiral HPLC analysis of modified products (see the Supporting Information).

formation of *trans* diastereomers as well as any erosion of enantiomeric purity as revealed by chiral HPLC analysis. Therefore, on the basis of a limited set of aryl halides, these results confirm that allylic boronate 7 displays a reaction scope comparable to that of 2.

In our previous investigation of the regiodivergent asymmetric Suzuki–Miyaura coupling of the dihydropyran allylboronate 2, we were unable to confirm unambiguously that the reaction proceeds with overall retention of stereochemistry.⁹ Our tentative assignment relied on a correlation with a natural product synthesized from the piperidine allylboronate 1. Here, we sought to obtain stronger evidence in support of a stereoretentive cross-coupling mechanism with dihydropyranyl allylboronates. To this end, we planned to prepare crystalline derivatives suitable for X-ray diffraction. Selective hydroboration of 11c followed by oxidation of the favored isomer gave 13 with a 3-hydroxy group *trans* to the phenyl and ethoxy substituents (Scheme 3). Likewise, the *trans*-diol 14 was synthesized as a


Scheme 3. Modification of Cross-Coupling Products



single diastereomer from 12c via an Upjohn dihydroxylation.¹⁵ The relevant spatial correlations obtained by NOE enhancement confirmed a 2,4-*cis* substitution for 13 and a 2,6-*cis* stereochemistry for 14. This assessment was further supported by the X-ray crystallographic data of 13 and 14 (see the Supporting Information).

Previous investigations into the mechanism of this allylic sp^3 – sp^2 cross-coupling reaction, with 1 and 2, concluded that, depending on the catalyst used, either a *syn*-S_E or *syn*-S_E' transmetalation occurs from an oxyborate-coordinated palladium species A (Scheme 4).^{8b,9,16} Both phosphine-based


Scheme 4. Proposed Ligand-Controlled Catalytic Cycle



ligands, SPhos and (4-CF₃C₆H₄)₃P, are believed to promote a S_E' transmetalation to form the η¹ γ-allylpalladium species B.^{8,9,16} When bound to a weaker σ-donating triarylphosphine, such as (4-CF₃C₆H₄)₃P, B may undergo isomerization to the higher valency π-allyl intermediate C, thus providing access via σ–π equilibration to the thermodynamic, heteroatom-conjugated σ-bonded Pd(II) complex D.⁹ This pathway leads to the α-isomers 5 and 11. On the other hand, strong σ-donor bulky ligands such as SPhos may suppress the formation of allylpalladium intermediate C with their well-known ability to promote a faster rate of reductive elimination.¹⁷ By virtue of this effect, the erosion of regioselectivity is minimized, leading to the kinetically favored γ-isomers 6/12. This effect may be further enhanced by the σ-inductive electron-withdrawing ethoxy group present in 7, which should lead to a faster reductive elimination.¹⁸

To establish the potential of this method toward the synthesis of biologically active polysubstituted pyrans containing an aryl substituent, we planned a synthesis of diospongins B. Diospongins B is a diarylheptanoid natural product that displays potent antiosteoporotic activity (Scheme 5).¹⁹ The synthesis began

Scheme 5. Synthesis of Diospongins B



with the selective epoxidation of 12c using *m*-CPBA, affording 15 in a 76% yield and 13:1 *anti*-selectivity.²⁰ It was followed with a selective epoxide ring opening using DIBALH followed by silyl protection of the hydroxyl group using chlorotriethylsilane (TESCl), which gave 17 with a 72% yield over two steps. Then, Mukaiyama-type addition onto the in situ generated oxocarbenium species favored the formation of the desired 2,6-*trans* product. The stereoselectivity can be rationalized by the nucleophilic addition onto the favored chairlike transition state²¹ and is supported by previous investigations toward the

synthesis of diospongin B.^{22a} After a final deprotection of the TES ether, the natural product was obtained in a 66% yield over two steps. Curiously, the sign of optical rotation of our synthetic diospongin B $[[\alpha]_D^{20} = +22.8$ (c 0.70, CHCl_3)] was opposite to the optical rotation of the isolated natural diospongin B $[[\alpha]_D^{20} = -23.4$ (c 0.60, CHCl_3)] as originally reported by Kadota and co-workers.¹⁹ Although the configurational assignment of **7** as well as the analysis of subsequent intermediates supported our stereochemical assignment, nearly all previous syntheses of diospongin B reported were consistent with Kadota's initial report and counter to our own.²² In the end, a recent asymmetric synthesis and detailed investigation into the absolute stereochemistry of diospongin B by Hashimoto and co-workers $[[\alpha]_D^{20} = +22.3$ (c 0.62, CHCl_3)]²³ as well as a corrigendum by Kadota supported our assignment.²⁴

In conclusion, the ligand-controlled stereoretentive and regio-divergent Suzuki–Miyaura cross-coupling of heterocyclic allylboronates was applied toward a 2-ethoxy dihydropyran boronate substrate (**7**) derived from a catalytic enantioselective inverse-electron demand oxa[4 + 2] cycloaddition. This method was systematically optimized for substrate **7**, and a scope similar to that for the des(2-ethoxy) analogue **2** was demonstrated with a representative set of aryl and alkenyl bromides. Both α - and γ -cross-coupling products can be obtained independently in high optical purity and with high regio- and diastereoselectivity. Through NMR and X-ray crystallographic analyses, the coupling step was determined to proceed with retention of stereochemistry. This method was applied to a concise synthesis and confirmation of absolute stereochemistry of diospongin B.

■ ASSOCIATED CONTENT

Supporting Information

The Supporting Information is available free of charge on the ACS Publications website at DOI: 10.1021/acs.orglett.5b01906.

- Experimental procedures, characterization data, and spectral reproductions for all new compounds (PDF)
- X-ray crystallographic data of compound **13** (CIF)
- X-ray crystallographic data of compound **14** (CIF)
- X-ray crystallographic data of compound **15** (CIF)

■ AUTHOR INFORMATION

Corresponding Author

*E-mail: dennis.hall@ualberta.ca.

Notes

The authors declare no competing financial interest.

■ ACKNOWLEDGMENTS

This research was supported by the Natural Science and Engineering Research Council (NSERC, Discovery Grant No. 203287-2012) of Canada and the University of Alberta. T.R. thanks the University of Alberta for a Queen Elizabeth II (QE II) Graduate Scholarship. We thank Mr. Hao Fu (Analytical and Instrumentation Laboratory at the University of Alberta) for help with chiral HPLC measurements and Dr. Robert McDonald (X-ray Crystallography at the University of Alberta) for X-ray crystallographic analyses of compounds **13**–**15**.

■ REFERENCES

- (1) (a) Elliott, M. C. *J. Chem. Soc. Perkin Trans. 1* **2002**, 2301–2323. (b) Yeung, K. S.; Paterson, I. *Chem. Rev.* **2005**, *105*, 4237–4313.
- (2) Lan, Y. H.; Chang, F. R.; Yang, Y. L.; Wu, Y. C. *Chem. Pharm. Bull.* **2006**, *54*, 1040–1043.
- (3) Tanaka, J.; Higa, T. *Tetrahedron Lett.* **1996**, *37*, 5535–5538.
- (4) Field, J. J.; Singh, A. J.; Kanakkanthara, A.; Halafih, T.; Northcote, P. T.; Miller, J. H. *J. Med. Chem.* **2009**, *52*, 7328–7332.
- (5) Biftu, T.; Sinha-Roy, R.; Chen, P.; Qian, X.; Feng, D.; Kuethe, J. T.; Scapin, G.; Gao, Y. D.; Yan, Y.; Krueger, D.; Bak, A.; Eiermann, G.; He, J.; Cox, J.; Hicks, J.; Lyons, K.; He, H.; Salituro, G.; Tong, S.; Patel, S.; Doss, G.; Petrov, A.; Wu, J.; Xu, S. S.; Sewall, C.; Zhang, X.; Zhang, B.; Thornberry, N. A.; Weber, A. E. *J. Med. Chem.* **2014**, *57*, 3205–3212.
- (6) Farmer, J. L.; Hunter, H. N.; Organ, M. G. *J. Am. Chem. Soc.* **2012**, *134*, 17470–17473.
- (7) Yang, Y.; Buchwald, S. L. *J. Am. Chem. Soc.* **2013**, *135*, 10642–10645.
- (8) (a) Glasspoole, B. W.; Ghazati, K.; Moir, J. M.; Crudden, C. M. *Chem. Commun.* **2012**, *48*, 1230–1232. (b) Chausset-Boissarie, L.; Ghazati, K.; LaBine, E.; Chen, J. L.-Y.; Aggarwal, V. K.; Crudden, C. M. *Chem. - Eur. J.* **2013**, *19*, 17698–17701.
- (9) Ding, J.; Rybak, T.; Hall, D. G. *Nat. Commun.* **2014**, *5*, 5474.
- (10) (a) Gao, X.; Hall, D. G. *J. Am. Chem. Soc.* **2003**, *125*, 9308–9309. (b) Deligny, M.; Carreaux, F.; Carboni, B.; Toupet, L.; Dujardin, G. *Chem. Commun.* **2003**, 276–277. (c) Deligny, M.; Carreaux, F.; Toupet, L.; Carboni, B. *Adv. Synth. Catal.* **2003**, *345*, 1215–1219. (d) Gao, X.; Hall, D.; Deligny, M.; Favre, A.; Carreaux, F.; Carboni, B. *Chem. - Eur. J.* **2006**, *12*, 3132–3142.
- (11) Gademann, K.; Chavez, D. E.; Jacobsen, E. N. *Angew. Chem.* **2002**, *114*, 3185–3187.
- (12) The synthesis of racemic **7**, which was used for the purpose of optimization of reaction conditions as well as chiral HPLC analysis, was performed efficiently using 1.5 mol % of Yb(fod)₃ as the catalyst and without the need of any drying agent.^{10b–d}
- (13) (a) Deligny, M.; Carreaux, F.; Carboni, B. *Synlett* **2005**, 1462–1464. (b) Gao, X.; Hall, D. G. *J. Am. Chem. Soc.* **2005**, *127*, 1628–1629. (c) Carreaux, F.; Favre, A.; Carboni, B.; Rouaud, I.; Boustie, J. *Tetrahedron Lett.* **2006**, *47*, 4545–4548. (d) Favre, A.; Carreaux, F.; Deligny, M.; Carboni, B. *Eur. J. Org. Chem.* **2008**, *2008*, 4900–4907. (e) Penner, M.; Rauniyar, V.; Kaspar, L. T.; Hall, D. G. *J. Am. Chem. Soc.* **2009**, *131*, 14216–14217.
- (14) The enantiomeric excess of **7** was measured on the corresponding secondary homoallylic alcohol produced from a highly diastereoselective allylboration with retention of stereochemistry (see the Supporting Information).¹⁰
- (15) VanRheenen, V.; Kelly, R. C.; Cha, D. Y. *Tetrahedron Lett.* **1976**, *17*, 1973–1976.
- (16) Yamamoto, Y.; Takada, S.; Miyaura, N.; Iyama, T.; Tachikawa, H. *Organometallics* **2009**, *28*, 152–160.
- (17) Martin, R.; Buchwald, S. L. *Acc. Chem. Res.* **2008**, *41*, 1461–1473.
- (18) Hartwig, J. F. *Inorg. Chem.* **2007**, *46*, 1936–1947.
- (19) Yin, J.; Kouda, K.; Tezuka, Y.; Tran, Q. L.; Miyahara, T.; Chen, Y.; Kadota, S. *Planta Med.* **2004**, *70*, 54–58.
- (20) The regioselectivity of **15** was confirmed by X-ray crystallographic data (see Supporting Information).
- (21) Ayala, L.; Lucero, C. G.; Romero, J. A. C.; Tabacco, S. A.; Woerpel, K. A. *J. Am. Chem. Soc.* **2003**, *125*, 15521–15528.
- (22) (a) Sawant, K. B.; Jennings, M. P. *J. Org. Chem.* **2006**, *71*, 7911–7914. (b) Kawai, N.; Hande, S. M.; Uenishi, J. *Tetrahedron* **2007**, *63*, 9049–9056. (c) Sabitha, G.; Padmaja, P.; Yadav, J. S. *Helv. Chim. Acta* **2008**, *91*, 2235–2239. (d) Wang, H.; Shuhler, B. J.; Xian, M. *Synlett* **2008**, *2008*, 2651–2654. (e) Kumaraswamy, G.; Ramakrishna, G.; Naresh, P.; Jagadeesh, B.; Sridhar, B. *J. Org. Chem.* **2009**, *74*, 8468–8471. (f) Stefan, E.; Nalin, A. P.; Taylor, R. E. *Tetrahedron* **2013**, *69*, 7706–7712.
- (23) Anada, M.; Washio, T.; Watanabe, Y.; Takeda, K.; Hashimoto, S. *Eur. J. Org. Chem.* **2010**, *2010*, 6850–6854.
- (24) See footnote 17 in ref 23.